News | August 16, 2021
Glenmark Pharmaceuticals net profit at Rs 306.52 crores in Q1FY22
The company reports revenue growth of 26% and PAT growth of 21% YoY
The company reports revenue growth of 26% and PAT growth of 21% YoY
The MoU was signed on World Organ Donation Day which falls on August 13
It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
Substantial reduction in losses
A treatment to prevent extreme symptoms and cut hospitalisation
Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasm
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
The company is eligible for 12 months exclusivity from launch
Subscribe To Our Newsletter & Stay Updated
